аЯрЁБс>ўџ !ўџџџўџџџ"џџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџ l ЩсСПРт\pThe Free Software Foundation Bфœ=PF0*8X@"Зк1Д Helvetica1ДCourier1Д Courier New1ДМ Courier New1Д Helvetica$#,##0_);($#,##0)$#,##0_);[Red]($#,##0)$#,##0.00_);($#,##0.00)$#,##0.00_);[Red]($#,##0.00)-**_($* #,##0_);_($* (#,##0);_($* "-"_);_(@_)*)'_(* #,##0_);_(* (#,##0);_(* "-"_);_(@_)5,2_($* #,##0.00_);_($* (#,##0.00);_($* "-"??_);_(@_)2+/_(* #,##0.00_);_(* (#,##0.00);_(* "-"??_);_(@_)2$#,##0.00;[Red]$#,##0.003$#,##0.00;[Red]($#,##0.00)4$#,##0;[Red]($#,##00)50.00%;[Red](0.00%)6 0%;[Red](0%)7#,##0.00;[Red](#,##0.00)8#,##0;[Red](#,##0)рѕџ Р рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР р Р р+ѕџ јР р)ѕџ јР р,ѕџ јР р*ѕџ јР р ѕџ јР р аˆ ~~Пр иˆ ~~Пр#иˆ ~~Пр иˆ ~~Пр8#мˆ ~~П“€џ“€џ“€џ“€џ“€џ“€џ’т8џџџџџџџџџџџџ€€€€€€€€€РРР€€€™™џ™3fџџЬЬџџffџ€€fЬЬЬџ€џџџџџџ€€€€€џЬџЬџџЬџЬџџ™™Ьџџ™ЬЬ™џџЬ™3fџ3ЬЬ™ЬџЬџ™џfff™–––3f3™f333™3™3f33™ЧЧЧ…&BSECURITIES AND EXCHANGE COMMISS…&сSECURITIES AND EXCHANGE COM (1)…$ЭPART I REGISTRANT INFORMATION… ] PART IV OTHER INFORMATION l Щ P  dќЉёвMbP?_*+‚€%џРŒ,Сƒ„&Тй­e2й?'Тй­e2й?(Тй­e2й?)Тй­e2й?Ё",D/р?р?ф!SECURITIES AND EXCHANGE COM (1)PART I REGISTRANT INFORMATIONPART IV OTHER INFORMATIONU } $ } m)} $ } Я ссссссссс с с с с сссссссссссARGOS THERAPEUTICS INCNT 10-Q 08/15/2018*"SECURITIES AND EXCHANGE COMMISSION    UNITED STATES    * "SECURITIES AND EXCHANGE COMMISSION     Washington, D.C. 20549           FORM 12b-25  #NOTIFICATION OF LATE FILINGSEC FILE NUMBER 001-35443 CUSIP NUMBER 040221 202$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/з4_ЬоџЫџЕџЉџ{џoџcџWџџвўtў"ўц§Ÿ§c§§ќИќpќ*ќќќъћ=PF0*8X> Ж@х l Щ є  dќЉёвMbP?_*+‚€%џРŒ,Сƒ„&Тй­e2й?'Тй­e2й?(Тй­e2й?)Тй­e2й?Ё",D/р?р?ф!SECURITIES AND EXCHANGE COMMISSPART I REGISTRANT INFORMATIONPART IV OTHER INFORMATIONU } <} $ } 0} $ }   ссссссссс с с с с сссссссссссARGOS THERAPEUTICS INCNT 10-Q 08/15/2018*"SECURITIES AND EXCHANGE COMMISSION (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D    o Form N-SAR  o Form N-CSR             For Period Ended:  June 30, 2018  (  o Transition Report on Form 10-K    (  o Transition Report on Form 20-F  ( o Transition Report on Form 11-K( o Transition Report on Form 10-Q)!o Transition Report on Form N-SAR( For the Transition Period Ended:$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/з4TЬоџЫџЕџЉџ{џoџcџWџРўTўўВ§V§њќžќBќхћ•ћ5ћ)ћћѕњ=PF0*8X> Ж@хb      l Щ ш  dќЉёвMbP?_*+‚€%џРŒ,Сƒ„&Тй­e2й?'Тй­e2й?(Тй­e2й?)Тй­e2й?Ё",D/р?р?ф!SECURITIES AND EXCHANGE COMMISS!SECURITIES AND EXCHANGE COM (1)PART IV OTHER INFORMATIONU } У1 ссссссссс с с с с ссссссссссссARGOS THERAPEUTICS INCNT 10-Q 08/15/2018%PART I REGISTRANT INFORMATION Argos Therapeutics, Inc. Full Name of Registrant  ! Former Name if Applicable 4233 Technology Drive-%Address of Principal Executive Office(Street and Number)$Durham, North Carolina 27704 City, State and Zip Code$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/з6šроџЫџЕџЉџ€џtџhџ\џ8џџ џ§ўиўЬўЋўzў[ўOў'ўўї§ы§У§=PF0*8X> Ж@ l Щ Z +ƒ5š=  dќЉёвMbP?_*+‚€%џРŒ,Сƒ„&Тй­e2й?'Тй­e2й?(Тй­e2й?)Тй­e2й?Ё",D/р?р?ф!SECURITIES AND EXCHANGE COMMISS!SECURITIES AND EXCHANGE COM (1)PART I REGISTRANT INFORMATIONU } U} <} $ }  } $ } a Zссссссссс с с с с сссссссссссссссссссARGOS THERAPEUTICS INCNT 10-Q 08/15/2018!PART IV OTHER INFORMATION~ ўџџџ6.Name and telephone number of person to contact & in regard to this notification   Richard Katz ~ Іёџџ  287-6315  (Name)   (Area Code)  (Telephone Number)  ~ њџџџ0 (Have all other periodic reports required3+under Section 13 or 15(d) of the Securities1)Exchange Act of 1934 or Section 30 of the1)Investment Company Act of 1940 during the/'preceding 12 months or for such shorter/'period that the registrant was required4,to file such report(s) been filed? If answer"is no, identify report(s).x Yes o No~ іџџџ.&Is it anticipated that any significant0(change in results of operations from the0(corresponding period for the last fiscal91year will be reflected by the earnings statements7/to be included in the subject report or portionthereof?зDаlоџЫџЕџЉџ„џxџlџ`џџтў„ўўўП§|§;§њќЛќ|ќ8ќќюћ˜ћ€ћ8ћјњИњxњ/њшљ с!с"с#с$с%с&с'с(с)с*с+с,с-с.с/с0с1с2с3с4с5с6с7с8с9с:с;с<с=с>с?с      x Yes o No!!!!!!"7"/If so, attach an explanation of the anticipated#4#,change, both narratively and quantitatively,$.$&and, if appropriate, state the reasons%0%(why a reasonable estimate of the results&&cannot be made.''(1()In April 2018, the Company terminated its)0)(development program for rocapuldencel-T,*6*.which it had been developing for the treatment+.+&of metastatic renal cell carcinoma and,8,0other cancers. As a result, the Company?s---%research and development expenses for.4.,the three and six months ended June 30, 2018/1/)are expected to be less than for the same070/periods in 2017. Due to the exploration1A19of the wide range of strategic alternatives2820discussed above, the Company is not able3>36to provide an estimate of results of operations44at this time.556"6Forward-looking statements77818)Except for statements of historical fact,919)the matters discussed in this Form 12b-25:/:'are ?forward-looking statements? within;0;(the meaning of the applicable securities<4<,laws and regulations. The words ?estimates?,=-=%?expects? and similar expressions are>,>$intended to identify forward-looking?4?,statements, although not all forward-lookingзD1 lЊџbџџзў™ўYў2ўўй§™§S§§ЭќќLќ ќФћsћ+ћнњГњ›њiњQњњЯљљPљ љЯј@сAсBсCсDсEсFсGсHсIсJсKсLсMсNсOсPсQсRсSсTсUсVсWсXсYс@,@$statements contain these identifyingA4A,words. Forward-looking statements, includingB4B,statements regarding the Company?s estimatesC2C*of its operating results for the three andD/D'six months ended June 30, 2018, involveE.E&risks and uncertainties that may causeF0F(actual results to differ materially fromG3G+those stated here. Factors that could causeH0H(actual results to differ materially fromI/I'those in the forward-looking statementsJ1J)include, but are not limited to, the riskK-K%that additional information may ariseL0L(from the completion of the review of theM0M(Company?s results of operations, as wellN2N*as other risks described more fully in theO7O/Company?s filings with the SEC. Forward-lookingP0P(statements reflect management?s analysisQ3Q+as of the date hereof. The Company does notR/R'undertake to revise these statements toS(S reflect subsequent developments.TTUV$W____________________________1X)Created by Morningstar Document Research.0Y(http://documentresearch.morningstar.com/з8ЯєФџ€џ<џњўЛў}ў=ўњ§К§{§:§§ќНќ}ќ;ќєћДћqћ2ћњњтњжњЪњЂњ=PF0*8X> Ж@хBYYXXWWSSRRQQPPOONNMMLLKKJJIIHHGGFFEEDDCCBBAA@@??>>==<<;;::9988664433221100//..--,,++**))((&&%%$$##""   Root Entryџџџџџџџџ РFўџџџBook џџџџџџџџџџџџ '@  ўџџџўџџџ§џџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџ